Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

OTHER_GOV × copper dotatate CU-64 × Clear all

Phase

Status

Sponsor Class

OTHER 3 INDUSTRY 2 OTHER_GOV 1

Study Type

Interventional 1

Sponsor

Cancer Type

NET 1 Endocrine 1

Conditions

Neuroendocrine Tumors 1

Interventions

Cisplatin 39 Capecitabine 35 Radiotherapy 28 Paclitaxel 28 Gemcitabine 28 Drug Therapy 28 apatinib 26 Cyclophosphamide 26 Carboplatin 26 Oxaliplatin 25 Irinotecan 24 Docetaxel 24 tislelizumab 23 Fluorouracil 21 Bevacizumab 21 Surgical Procedures, Operative 18 Nivolumab 17 pembrolizumab 16 Exercise 15 fludarabine 14 camrelizumab 14 Radiation 14 Metformin 14 Blood Specimen Collection 14 S 1 (combination) 13 Control Groups 12 Standard of Care 10 Pemetrexed 10 Vinorelbine 9 Tamoxifen 9

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT02125474 2019-11-14

Efficacy of 177-Lu-DOTA 0, Tyr 3 Octreotate

Instituto Nacional de Cancerologia, Columbia

Phase NA Completed

Neuroendocrine Tumors

Data powered by HemOnc (CC BY 4.0) Colophon ⚡